SFDA Officially Kicks Off Safety Reappraisal Of TCM Injections
This article was originally published in PharmAsia News
China's State FDA has officially started reappraising the safety of TCM injections (PharmAsia News, July 22, 2009). Of the total 143 products, Shuanghuanglian and Shenmai injections are listed as the first batch for reassessment. SFDA officials said that the agency will focus on safety assurance and carry out the work on three levels - risk inspection, comprehensive evaluation and standards elevation. The agency will conduct risk assessments on major TCM injections by stages and groups. In addition, medicine producers must conduct risk assessments themselves during their production process for quality control. SFDA will prioritize and accelerate the raising of national TCM injection quality by issuing the standards in batches. (Click here for more - Chinese language)
You may also be interested in...
SHANGHAI - Three deaths caused by adverse drug reactions allegedly linked to use of herbal injection Shuanghuanglian have raised wider concerns over the safety of herbal injections in China
Discovery Research In Japan By Global Pharmaceutical Outfits: Evolving More Toward Partnerships? (Part 1 of 3)
Several multinational pharmaceutical companies have shut down their Japan-based discovery research facilities over the last few years. Some, instead, are relying more on partnerships with local drug research entities in Japan. PharmAsia News' Tokyo bureau examines the factors behind the trend in this first article in a three-part series on the subject.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.